Company Overview and News

APFT appoints two new directors

2018-10-03 theedgemarkets
KUALA LUMPUR (Oct 3): APFT Bhd has appointed Datuk Tan Choon Hwa and Tan Sri Zaini Omar as new non-executive directors effective today.

KLCI erases earlier loss, crosses 1,800-level

2018-09-27 theedgemarkets
KUALA LUMPUR (Sept 27): The FBM KLCI erased its earlier losses and rose at mid-morning to cross the 1,800-point level.
5072 8621 7158 BATS 4162 7215 2089 5199 5347 3301 7668 TNABY AXXTF HIPEF PNAGF UPBMF 1163 5202 8311 6033 2593 5139 PNADF 0900 6888 TNABF 3719

Ni Hsin up 4.25% on positive technicals

2018-09-21 theedgemarkets
KUALA LUMPUR (Sept 21): Ni Hsin Resources Bhd shares rose 4.25% this morning following a positive technical outlook for the stock.

Ni Hsin Resources may trend higher, says RHB Retail Research

2018-09-21 theedgemarkets
KUALA LUMPUR (Sept 21): RHB Retail Research said Ni Hsin Resources Bhd may trend higher after it formed another white candle and breached above the 22 sen threshold.

Stock With Momentum: Ni Hsin Resources

2018-09-19 theedgemarkets
Ni Hsin Resources Bhd (+ve) Trading of shares in Ni Hsin Resources Bhd (fundamental: 1.8, valuation: 0.9) triggered our momentum algorithm yesterday for the first time this year. The stock closed up 1.5 sen or 7.69% at 21 sen.

4.1% in Caely traded off-market

2018-09-03 theedgemarkets
KUALA LUMPUR (Sept 3): Ladies undergarment manufacturer Caely Holdings Bhd saw 3.3 million shares, or 4.08% of the group's 80.92 million shares, crossed off-market today.
7215 BSMAF 7154 1818

Caely shares fall on profit-taking

KUALA LUMPUR: Caely Holdings Bhd ’s shares were traded lower in morning trade Friday as investors take profit after the recent gains.
7215 7154

Caely plans tie-up with China lingerie firms

KUALA LUMPUR: Undergarments manufacturer Caely Holdings Bhd is in talks with several China-based lingerie companies to expand its earnings and business prospects. The company announced on Monday this was part of its strategy to expand its market share by working with lingerie companies in the region. Caely sells its products in Malaysia and it also exports to Europe, Canada, the US and other countries.
7215 7154

Trading ideas: Ni Hsin, Caely, Comfort Gloves, Suria Capital, MMC

KUALA LUMPUR: Ni Hsin Resources Bhd , Caely Holdings Bhd , Comfort Gloves Bhd , Suria Capital Holdings Bhd and MMC Corp Bhd are among the stocks to watch on Monday, according to JF Apex Research.
0045 2127 6521 7215 7154

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...